Back to top
more

Sutro Biopharma (STRO)

(Real Time Quote from BATS)

$3.51 USD

3.51
80,048

+0.01 (0.29%)

Updated Oct 2, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 326% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 293.4% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

by Zacks Equity Research

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study

by Zacks Equity Research

Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

by Zacks Equity Research

Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

by Zacks Equity Research

Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

by Zacks Equity Research

Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.

How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 288%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 288.1% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia

by Zacks Equity Research

bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.

Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

by Zacks Equity Research

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

Wall Street Analysts Think Sutro Biopharma, Inc. (STRO) Could Surge 295%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

by Zacks Equity Research

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration

by Zacks Equity Research

Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?

by Zacks Equity Research

Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sutro Biopharma, Inc. (STRO) Moves 6.4% Higher: Will This Strength Last?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.